clinical trials for semaglutide 7.2 mg trial SELECT U.S. FDA Post hoc analysis of SUSTAIN

The maintenance frequency approach where intensive initial treatment transitions to reduced ongoing application (2-4 times weekly) provides middle ground sustaining benefits while minimizing costs and commitment intensity

GLP-1 agonists might address these comorbidities while potentially influencing underlying inflammation

But theres another challenge: since GLP-1s reduce appetite, people often eat much less

Any significant changes in symptoms such as increased fatigue, yellowing of eyes or skin, abdominal pain, or unexplained bruising should prompt immediate medical consultation rather than self-treatment with supplements